Knapp C M, Lee K, Foye M, Ciraulo D A, Kornetsky C
Department of Psychiatry, Boston University School of Medicine, MA 02118, USA.
Life Sci. 2001 Aug 24;69(14):1673-82. doi: 10.1016/s0024-3205(01)01249-8.
Evidence from cocaine self-administration studies suggests that increasing the activity of cyclic AMP (cAMP) pathways within the nucleus accumbens may produce a reduction in cocaine's reinforcing effects. Rolipram may increase intra-cellular levels of cAMP by selectively inhibiting Type IV phosphodiesterases, enzymes that catalyze cAMP breakdown. The present study was undertaken to test the hypothesis that infusion of rolipram into the nucleus accumbens would decrease cocaine-induced enhancement of the sensitivity of brain stimulation reward (BSR) pathways. BSR thresholds were determined in rats after the systemic administration of cocaine (4 mg/kg IP) and the infusion of rolipram (0.2 microg/side) into the nucleus accumbens both alone and in combination. Thresholds also were determined after the systemic administration of rolipram alone and, as a positive control, for amphetamine (10 microg/side) infused into the nucleus accumbens. BSR thresholds were significantly lowered below baseline levels following d-amphetamine administration suggesting that cannulae were in place to allow perfusion of reward pathways. Compared to values for saline alone, thresholds were lower after the injection of cocaine (4 mg/kg IP) or the infusion of rolipram (0.2 microg/side) into the nucleus accumbens. Treatment with the combination of cocaine and intra-nucleus accumbens rolipram produced a greater lowering of the BSR threshold than did administration of either rolipram or cocaine alone. Systemic administration of rolipram (0.5 mg/kg IP) either blocked the effects of BSR or raised BSR thresholds and produced stimulation-induced head jerking in most of the test animals. These results suggest that infusion into the nucleus accumbens of rolipram, an agent that putatively elevates cAMP levels in this structure, can enhance the sensitivity of reward pathways to BSR and can augment cocaine's actions on these pathways.
来自可卡因自我给药研究的证据表明,增强伏隔核内环磷酸腺苷(cAMP)信号通路的活性可能会降低可卡因的强化作用。咯利普兰可能通过选择性抑制IV型磷酸二酯酶来提高细胞内cAMP水平,IV型磷酸二酯酶是催化cAMP分解的酶。本研究旨在验证以下假设:向伏隔核内注入咯利普兰会降低可卡因诱导的脑刺激奖赏(BSR)通路敏感性增强。分别单独及联合向大鼠伏隔核内注入咯利普兰(0.2微克/侧)和腹腔注射可卡因(4毫克/千克)后,测定其BSR阈值。还分别单独向大鼠腹腔注射咯利普兰及向伏隔核内注入苯丙胺(10微克/侧)作为阳性对照后,测定其BSR阈值。注射d-苯丙胺后,BSR阈值显著低于基线水平,表明插管位置正确,可用于奖赏通路的灌注。与单独注射生理盐水的值相比,向伏隔核内注射可卡因(4毫克/千克)或咯利普兰(0.2微克/侧)后,阈值降低。可卡因与伏隔核内咯利普兰联合治疗比单独给予咯利普兰或可卡因更能降低BSR阈值。腹腔注射咯利普兰(0.5毫克/千克)要么阻断BSR效应,要么提高BSR阈值,并在大多数实验动物中产生刺激诱导的头部抽搐。这些结果表明,向伏隔核内注入咯利普兰(一种可能提高该结构中cAMP水平的药物)可增强奖赏通路对BSR的敏感性,并可增强可卡因对这些通路的作用。